Join Now

Utah Life Sciences News & Events

Signpath Pharma

May 14, 2021

Signpath Pharma (Signpath) has developed a platform technology (the CorreQT platform) which mitigates the cardiac side effects of other drugs, including cardiac arrhythmia and cardiac damage associated with chemotherapy. The company has partnerships and working relationships with laboratories, hospitals, and other companies in Canada, Europe, the U.S., and Asia. Using the CorreQT technology, Signpath is developing heart-safe versions of FDA approved drugs which cause dangerous arrhythmia side effects. Clinical testing for these targets is expected to begin in 2020.